Oct 28 (Reuters) - UCB SA : * Phase 3 clinical study evaluating VIMPAT (lacosamide) meets its primary efficacy endpoint * Study evaluated VIMPAT as adjunctive therapy in treatment of Japanese and Chinese adult patients with partial-onset ... Reuters UK, 2 days ago
9/15/14 - New indication for VIMPAT® lacosamide: UCB's anti-epileptic drug approved by FDA as monotherapy in the treatment of patients with partial-onset...
9/15/14 - New indication for VIMPAT lacosamide: UCB's anti-epileptic drug approved by FDA as monotherapy in the treatment of patients with partial-onset... New indication for VIMPAT lacosamide: UCB's anti-epileptic drug approved by FDA as ...Pharmacy Choice, 1 month ago FDA Okays Lacosamide Monotherapy in Partial-Onset Seizures Diabetes Care, 1 month ago New Indication for Anti-Epileptic Drug Lacosamide (Vimpat) Pharmscope, 1 month ago New indication for VIMPAT® (lacosamide): UCB's anti-epileptic drug approved by FDA as monotherapy in the treatment of patients with partial-onset seizures PR Newswire, 1 month ago
By a News Reporter-Staff News Editor at Biotech Week -- Ranbaxy Laboratories Limited ( New Delhi , IN) has been issued patent number 8853453, according to news reporting originating out of Alexandria, Virginia , by NewsRx editors (see also ...4 Traders, 2 weeks ago
Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com
This report provides comprehensive information on the therapeutic development for Partial Seizure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) ...Digital Journal, 1 week ago Global Sales of Epilepsy Drugs Market to Grow $5.35 billion by 2022 Says a New Report Available at MarketOptimizer.org SearchBug, 1 month ago
More from: Red Orbit, Stock Nod...and 35 other sources
The latest FDA notification includes 32 products with safety labeling changes. This relates to boxed warnings, contradictions, precautions, and adverse reactions. Some of the more commonly used medications on the list include Nicorette. This product ...Digital Journal, 1 month ago
Patent Application Titled "A Pharmaceutical Composition Comprising the Phytocannabinoids Cannabidivarin (Cbdv) and Cannabidiol (Cbd)" Published Online
By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C. , by NewsRx journalists, a patent application by the inventors Whalley, Benjamin (Reading, GB); Williams, Claire (Reading, GB); ...4 Traders, 1 month ago
Epileptic seizures affect approximately 3 million Americans; many of them have their seizures well controlled by medication; however, some continue to suffer from seizures despite treatment . This severely impacts their quality of life. Now, a new ...Examiner.com, 1 month ago Fish Oil May Ease Tough-To-Treat Epilepsy, University of California, Los Angeles (UCLA) Study BioSpace, 1 month ago Low-doses of fish oil may reduce seizures in patients with drug-resistant epilepsy Noodls, 1 month ago
Oncology/Hematology Published: Sep 3, 2014 ByMedPage Today Staff No survival benefit was seen with double mastectomy in breast cancer patients, compared with breast-conserving surgery and radiotherapy, a JAMA study found . Sanofi's ...MedPage Today, 1 month ago
The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment according to the Act on the ...News-Medical.Net, 2 months ago Perampanel for epilepsy: Still no proof of added benefit EurekAlert!, 2 months ago Still no proof of added benefit for perampanel in epilepsy Medical News Today, 2 months ago
on your WebpageAdd Widget >Get your members hooked!